Since then, the Gal-9/TIM-3 axis has received special attention from scientists working in the field of cancer immunotherapy and is now considered a mechanism of resistance when using ICIs in cancer patients [113,114,115,116]. This evidence concerns the gene HAVCR2 and cancer.